Compounds > 2-benzylaminopyridine
Page last updated: 2024-11-05

2-benzylaminopyridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID23362
CHEMBL ID391815
SCHEMBL ID2230559
MeSH IDM0061942

Synonyms (48)

Synonym
AC-5949
CBMICRO_010916
n-benzyl-n-(2-pyridinyl)amine
DIVK1C_004532
ENAMINE_005854
nsc-59833
nsc59833
2-(benzylamino)pyridine
pyridine, 2-(benzylamino)-
CDS1_003492
IDI1_008089
6935-27-9
2-pyridinamine, n-(phenylmethyl)-
n-benzylpyridin-2-amine
2-benzylaminopyridine, 98%
STK144786
2-benzylaminopyridine
n-(2-pyridyl)benzylamine
b1209 ,
CHEMBL391815 ,
HMS1410K02
wyhxnqxdqqmtqi-uhfffaoysa-
n-(phenylmethyl)pyridin-2-amine
inchi=1/c12h12n2/c1-2-6-11(7-3-1)10-14-12-8-4-5-9-13-12/h1-9h,10h2,(h,13,14)
AKOS000120341
unii-2m6w78559o
nsc 59833
ai3-19227
einecs 230-060-5
2m6w78559o ,
FT-0611308
DTXSID9064508
SCHEMBL2230559
W-203541
W-106237
n-benzyl-n-(2-pyridinyl)amine #
mfcd00006251
F2190-0410
STR05313
Q27254943
D86502
ethyl2-cyano-3-(2-thienyl)acrylate
SB52306
9vo ,
bdbm50534542
EN300-15570
SY049216
Z31196921
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty acid-binding protein, liverHomo sapiens (human)Kd300.00000.20000.55000.9000AID1632106
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (12)

Processvia Protein(s)Taxonomy
long-chain fatty acid transportFatty acid-binding protein, liverHomo sapiens (human)
positive regulation of fatty acid beta-oxidationFatty acid-binding protein, liverHomo sapiens (human)
response to vitamin B3Fatty acid-binding protein, liverHomo sapiens (human)
negative regulation of apoptotic processFatty acid-binding protein, liverHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processFatty acid-binding protein, liverHomo sapiens (human)
intestinal absorptionFatty acid-binding protein, liverHomo sapiens (human)
cellular response to hydrogen peroxideFatty acid-binding protein, liverHomo sapiens (human)
cellular response to hypoxiaFatty acid-binding protein, liverHomo sapiens (human)
cellular oxidant detoxificationFatty acid-binding protein, liverHomo sapiens (human)
fatty acid transportFatty acid-binding protein, liverHomo sapiens (human)
lipid metabolic processGastrotropinHomo sapiens (human)
negative regulation of cell population proliferationGastrotropinHomo sapiens (human)
fatty acid transportGastrotropinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
chromatin bindingFatty acid-binding protein, liverHomo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, liverHomo sapiens (human)
protein bindingFatty acid-binding protein, liverHomo sapiens (human)
phospholipid bindingFatty acid-binding protein, liverHomo sapiens (human)
antioxidant activityFatty acid-binding protein, liverHomo sapiens (human)
bile acid bindingFatty acid-binding protein, liverHomo sapiens (human)
oleic acid bindingFatty acid-binding protein, liverHomo sapiens (human)
heterocyclic compound bindingFatty acid-binding protein, liverHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, liverHomo sapiens (human)
lipid bindingGastrotropinHomo sapiens (human)
fatty acid bindingGastrotropinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (9)

Processvia Protein(s)Taxonomy
nucleoplasmFatty acid-binding protein, liverHomo sapiens (human)
peroxisomal matrixFatty acid-binding protein, liverHomo sapiens (human)
cytosolFatty acid-binding protein, liverHomo sapiens (human)
apical cortexFatty acid-binding protein, liverHomo sapiens (human)
extracellular exosomeFatty acid-binding protein, liverHomo sapiens (human)
protein-containing complexFatty acid-binding protein, liverHomo sapiens (human)
nucleusFatty acid-binding protein, liverHomo sapiens (human)
cytosolFatty acid-binding protein, liverHomo sapiens (human)
cytoplasmGastrotropinHomo sapiens (human)
cytosolGastrotropinHomo sapiens (human)
membraneGastrotropinHomo sapiens (human)
nucleusGastrotropinHomo sapiens (human)
cytosolGastrotropinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (16)

Assay IDTitleYearJournalArticle
AID627646Cytotoxicity against human MCF7 cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID627545Antimicrobial activity against Staphylococcus aureus SG511 after 24 hrs by Kirby-Bauer agar diffusion assay2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID627644Antimicrobial activity against Staphylococcus aureus SG511 assessed after 18 hrs by broth microdilution method2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID627643Antimicrobial activity against Micrococcus luteus ATCC 10240 assessed after 18 hrs by broth microdilution method2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID1632107Binding affinity to recombinant human N-terminal His6 and Avi-tagged FABP6 expressed in Escherichia coli NEB cells at 200 uM by surface plasmon resonance method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6).
AID1632105Binding affinity to recombinant human N-terminal His6 and Avi-tagged FABP6 expressed in Escherichia coli NEB cells at 250 uM by surface plasmon resonance method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6).
AID1632104Binding affinity to recombinant human N-terminal His6 and Avi-tagged FABP6 expressed in Escherichia coli NEB cells by surface plasmon resonance method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6).
AID627547Antimicrobial activity against Enterococcus faecalis ATCC 49532 after 24 hrs by Kirby-Bauer agar diffusion assay2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID627645Antimicrobial activity against Enterococcus faecalis ATCC 49532 assessed after 18 hrs by broth microdilution method2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID1632108Binding affinity to recombinant human N-terminal His6 and Avi-tagged FABP6 expressed in Escherichia coli NEB cells at 200 uM in presence of taurocholate by surface plasmon resonance method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6).
AID627544Antimicrobial activity against Micrococcus luteus ATCC 10240 after 24 hrs by Kirby-Bauer agar diffusion assay2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID627542Cytotoxicity against human PC3 cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID1632106Binding affinity to recombinant human N-terminal His6 and Avi-tagged FABP1 expressed in Escherichia coli NEB cells by surface plasmon resonance method2016Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
Identification and Investigation of Novel Binding Fragments in the Fatty Acid Binding Protein 6 (FABP6).
AID627543Cytotoxicity against human HeLa cells2011Journal of medicinal chemistry, Oct-13, Volume: 54, Issue:19
N-O chemistry for antibiotics: discovery of N-alkyl-N-(pyridin-2-yl)hydroxylamine scaffolds as selective antibacterial agents using nitroso Diels-Alder and ene chemistry.
AID301909Growth inhibition of mouse L929 cells after 5 days by MTT assay2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Efficient one-pot synthesis of biologically active polysubstituted aromatic amines.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (20.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.01 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
tacrine
Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.		2.1310acridines;
aromatic amine		EC 3.1.1.7 (acetylcholinesterase) inhibitor
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.0610aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
benzohydroxamic acid
[no description available]		2.0610
alpha-aminopyridine
alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.		1.9510
aminomebendazole
aminomebendazole: structure in first source		2.1310benzophenones
n-benzyl-4-toluidine
[no description available]		2.0310
N-hydroxy-2-phenylacetamide
[no description available]		2.0610acetamides
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.0610antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Dermatitis Medicamentosa
[description not available]		01.9510